Position in ALEC
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,904,877
+$1,335,263 QoQ
Shares Held
1,351,106
+34.3% QoQ
Ownership
1.22%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ALEC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Eversept Partners, LP holds $675,198,480 across 57 Biotechnology names. ALEC ranks #31 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
934,423 | $104,048,001 | |
| 2 | VERA |
Vera Therapeutics, Inc.
|
2,173,286 | $87,431,295 | |
| 3 | SNDX |
Syndax Pharmaceuticals Inc
|
2,885,622 | $67,408,129 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
1,788,016 | $56,715,867 | |
| 5 | PCVX |
Vaxcyte, Inc.
|
924,193 | $53,704,855 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
632,100 | $47,464,389 | |
| 7 | GERN |
Geron Corp
|
18,834,883 | $28,063,975 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
542,610 | $16,120,943 |
All Filings in ALEC
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,904,877 | 1,351,106 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,569,614 | 1,006,163 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $4,406,626 | 1,488,725 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,780,500 | 1,986,072 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $759,424 | 617,418 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $378,179 | 200,095 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $1,550,642 | 332,756 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,459,495 | 541,739 | Shares | Sole | 2024-08-14 | |
| 2024-03-31 | $3,227,749 | 536,171 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||